id
name
related bits
133
processing priority
4
site type
0 (generic, awaiting analysis)
review version
11
html import
20 (imported)
first seen date
2023-10-09 08:41:21
expired found date
-
created at
2024-05-30 04:20:56
updated at
2026-03-11 00:32:59
length
13
crc
29270
tld
2211
nm parts
0
nm random digits
0
nm rare letters
0
is subdomain of id
-
previous id
0
replaced with id
0
related id
-
dns primary id
dns alternative id
0
lifecycle status
0 (unclassified, or currently active)
deleted subdomains
0
page imported products
0
page imported random
0
page imported parking
0
count skipped due to recent timeouts on the same server IP
0
count content received but rejected due to 11-799
0
count dns errors
0
count cert errors
0
count timeouts
1
count http 429
0
count http 404
28
count http 403
0
count http 5xx
0
next operation date
-
server bits
—
server ip
-
mp import status
20
mp rejected date
-
mp saved date
-
mp size orig
53522
mp size raw text
7125
mp inner links count
19
mp inner links status
20 (imported)
title
Home
description
Global pharma news, biotech, clinical research, life sciences & healthcare. Pharma Events Listings, Pharma Company Directory, Pharma Jobs.
site name
PharmiWeb.com
author
updated
2025-12-10 00:01:58
raw text
PharmiWeb.com: The Heart of Life Sciences on the Web Post a Job Find a Job Upload Content Search jobs PharmiWeb Today Story Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRAS G12C Inhibitor Approved by the U.S. FDA for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring a KRAS G12C Mutation and Who Have Received at Least One Prior Systemic Treatment KRAZATI is in Clinical Development in Combination with a PD-1 Inhibitor as a First-Line Therapy for Patients with Non-Small Cell Lung Cancer Harboring a KRAS G12C Mutation as well as in Other Indications Mirati’s Promising Pipeline...
redirect type
0 (-)
block type
0 (no issues)
detected language
1 (English)
category id
index version
2025110801
spam phrases
0
text nonlatin
0
text cyrillic
0
text characters
4606
text words
857
text unique words
413
text lines
127
text sentences
25
text paragraphs
10
text words per sentence
34
text matched phrases
3
text matched dictionaries
5
links self subdomains
0
links other subdomains
links other domains
17 - pharmiweb.jobs
links spam adult
0
links spam random
0
links spam expired
0
links ext activities
0
links ext ecommerce
0
links ext finance
0
links ext crypto
0
links ext booking
0
links ext news
0
links ext leaks
0
links ext ugc
links ext klim
0
links ext generic
2
dol status
0
dol updated
2025-12-10 00:01:58
rss path
rss status
3 (priority 3 already searched, no matches found)
rss found date
-
rss size orig
0
rss items
0
rss spam phrases
0
rss detected language
0 (awaiting analysis)
inbefore feed id
-
inbefore status
0 (new)
sitemap path
sitemap status
30 (processing completed, results pushed to table crawler_sitemaps.ext_domain_sitemap_lists)
sitemap review version
2
sitemap urls count
32767
sitemap urls adult
5
sitemap filtered products
15
sitemap filtered videos
31
sitemap found date
2023-12-31 08:35:32
sitemap process date
2025-03-02 17:41:37
sitemap first import date
-
sitemap last import date
-